Clobazam治疗难治性癫痫:加拿大的经验。一个回顾性研究。加拿大Clobazam合作集团。

文章的细节

引用

复制到剪贴板

作者不明

Clobazam治疗难治性癫痫:加拿大的经验。一个回顾性研究。加拿大Clobazam合作集团。

Epilepsia。1991 May-Jun; 32 (3): 407 - 16。

PubMed ID

2044502 (在PubMed

]

文摘

在过去7年在加拿大,已经有超过1300名难治性癫痫患者治疗clobazam (CLB) 104成人和儿科神经学家。使用一个标准的病例报告,32个神经病学家,他每一个大于或等于10个病人治疗,877例回顾性数据提供。人口有以下特点;儿童和成人的比例都有51个和49%,分别;38%的病人是智障;单个和多个发作类型疾病的百分比是46和54%,分别;和成人有更多的复杂部分发作,而孩子有更多的非典型的缺席和肌阵挛类型。clobazam之前,患者平均2其他抗癫痫药物(aed)(范围0 - 5 aed)。儿童CLB的平均剂量为0.87毫克/公斤/天(范围0.05 - -3.8毫克/公斤/天)和成人30毫克/天(范围-150 - 2.5毫克/天)。CLB治疗范围从几天时间大于4年,40%的人接受治疗大于1年。 Using Kaplan-Meier curves, we found that 4 years after starting, 40-50% of patients continued CLB. More than 40% of patients with single seizure type had at least a 50% reduction in seizure frequency (improved). At least 60% of patients with multiple seizure type had improvement in one or more seizure types, and nearly 40% of the patients had all their seizure types improved. The seizure frequency for each seizure type, except tonic, was reduced greater than 50% in 40-50% of patients and by 100% in 10-30% of patients. Twenty percent stopped CLB for poor efficacy, 4% stopped for safety-related reasons including drug interactions, and 8% stopped for both reasons. Possible side effects (predominantly somnolence) were reported by 32%; however, in only 11% were the side effects sufficiently severe to cause discontinuation of medication. "Tolerance," leading to discontinuation of CLB, was reported for 9%. Patients treated with CLB for at least 1 year were generally maintained with CLB greater than 1 year. Thus, CLB is useful in refractory epilepsy of all types, suggesting that a monotherapy trial in less severe epilepsy is now desirable.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

Clobazam